Skip to main content
. 2020 Sep 4;7:2049936120952604. doi: 10.1177/2049936120952604

Table 1.

In vitro activity of plazomicin in Gram-negative organisms.

Organism % S MIC50/90 (µg/mL) Range (µg/mL)
Gram negative
 Enterobacteriaceae
  Enterobacteriaceae (n = 254)6 80 1/4 ⩽0.25–>64
  Enterobacteriaceae (n = 4217)12 95.8 0.5/2 ⩽0.06–>128
   blaKPC (n = 113) 92.9 0.25/2 ⩽0.25–>128
   MBL (n = 37) 40.5 128/>128 ⩽0.25–>128
   blaOXA-48-like (n = 54) 87 0.25/16 ⩽0.25–>128
   Carbapenemase-negative (n = 59) 94.9 0.25/1 ⩽0.25–>128
   AME genes (n = 728) 99 0.25/1 ⩽0.25–16
   aac(6′)-Ib (n = 585) 99.3 0.25/1 ⩽0.25–16
   aac(3)-IIa (n = 453) 98.9 0.25/1 ⩽0.25–16
   16S rRNA methyltransferase (n = 60) 0 >128/>128 128–>128
  Enterobacteriaceae (n = 499)16 NA 0.5/64 ⩽0.125–>64
   KPC-2 (n = 389) 85 0.5/>64 ⩽0.125–>64
   NDM-1 (n = 81) 80 0.5/16 ⩽0.125–>64
  Enterobacteriaceae (n = 4362)14 96.4 0.5/2 ⩽0.06–>128
   CRE (n = 97) 99a 0.5/1 ⩽0.06–>128
   blaKPC (n = 87) 98.9a 0.25/1 ⩽0.06–>128
  MDR Enterobacteriaceae (n = 300)15 96 1/2 ⩽0.25–4
  MBL (n = 488)17 76.4 1/>64 ⩽0.12–>64
 Klebsiella species
  K. pneumoniae (n = 1429)12 95.8 0.25/0.5 ⩽0.06–>128
  K. oxytoca (n = 317)12 100 0.5/0.5 0.12–2
  K. aerogenes (n = 129)12 100 0.5/1 ⩽0.06–2
  K. aerogenes (n = 120)14 99.2 0.5/1 ⩽0.06–4
  K. pneumoniae (n = 1506)14 99.8 0.25/0.5 ⩽0.06–>128
  K. oxytoca (n = 359)14 99.2 0.5/0.5 ⩽0.06–>128
  K. pneumoniae (n = 241)15 95 1/2 ⩽0.5–4
  K. pneumoniae (n = 395)18 NA 0.25/0.5 ⩽0.12–>64
  K. pneumoniae (n = 1039)19 99.8 0.25/0.5 ⩽0.12–>64
  K. oxytoca (n = 279)19 100 0.25/0.5 ⩽0.12–2
  K. pneumoniae (n = 1155)20 NA 0.5/1 0.12–>8
 Escherichia coli
  E. coli (n = 1399)12 99.4 0.5/1 0.12–16
  E. coli (n = 1346)14 99.4 0.5/1 ⩽0.06–>128
  E. coli (n = 1146)18 NA 0.5/1 ⩽0.12–4
  E. coli (n = 3094)19 99.5 0.5/1 ⩽0.12–>64
   MDR (n = 358) 99.4 0.5/1 ⩽0.12–>64
  E. coli (n = 3050)20 NA 0.5/1 ⩽0.06–>8
 Enterobacter species
  E. cloacae (n = 104)14 100 0.5/0.5 0.12–2
  E. cloacae (n = 470)19 100 0.25/0.5 ⩽0.12–2
 Serratia marcescens
  S. marcescens (n = 105)12 99 1/1 0.25–8
  S. marcescens (n = 107)14 97.2 1/2 0.12–4
  S. marcescens (n = 255)19 97.6 0.5/1 ⩽0.12–8
 Citrobacter species
  C. freundii (n = 131)12 99.2 0.5/1 0.12–4
  C. koseri (n = 145)12 100 0.25/0.5 ⩽0.06–1
  C. freundii (n = 159)14 99.4 0.5/1 0.12–4
  C. koseri (n = 145)14 99.3 0.25/0.5 ⩽0.06–4
 Proteus species
  P. mirabilis (n = 119)12 74.8 2/4 0.5–>128
  P. vulgaris group (n = 109)12 91.7 1/2 0.25–8
  P. mirabilis (n = 124)14 82.3 2/4 0.25–8
  P. vulgaris group (n = 116)14 88.8 2/4 0.5–16
  P. mirabilis (n = 235)19 44.3 4/4 0.5–32
 Other Enterobacteriaceae
  Morganella morganii (n = 131)12 68.7 2/4 0.25–16
  Providencia spp. (n = 84)12 67.9 2/8 0.5–>128
  Morganella morganii (n = 118)14 64.4 2/4 0.5–64
  Providencia spp. (n = 158)14 63.3 2/4 0.12–64
  Morganella morganii (n = 54)19 66.7 2/4 0.25–8
 Pseudomonas aeruginosa
  P. aeruginosa (n = 593)18 NA 4/16 ⩽0.12–>64
  P. aeruginosa (n = 1789)19 NA 4/16 ⩽0.12–>64
   MDR (n = 256) NA 8/64 ⩽0.12–>64
  P. aeruginosa (n = 679)21 NA 8/32 0.12–>64
 Acinetobacter species
  Acinetobacter spp. (n = 82)6 NA 8/32 0.5–>64
  Acinetobacter spp. (n = 99)12 NA 8/>128 ⩽0.06–>128
  Acinetobacter spp. (n = 95)14 NA 2/16 ⩽0.06–>128
  A. baumannii (n = 68)19 NA 1/8 0.25–>64
  A. baumannii (n = 407)21 NA 8/16 0.12–>64

Food and Drug Administration susceptibility breakpoint is used for plazomicin (⩽2 µg/mL).10

a

Study reported % susceptibility using a susceptibility breakpoint of ⩽4 µg/mL.

MIC50/90 – minimum inhibitory concentration needed to inhibit 50% and 90% of the included isolates, respectively aac, n-acetyltransferase; AME, aminoglycoside modifying enzyme; bla, beta-lactamase gene; CRE, carbapenem-resistant Enterobacteriaceae; KPC, Klebsiella pneumoniae carbapenemase; MBL, metallo-beta-lactamase; MDR, multi-drug resistant; NA, data not included in study; NDM, New Delhi metallo-beta-lactamase; OXA, oxacillinase; S, susceptible; spp., species